




ATTORNEYS AT LAW



09/501730

Co/JC AS  
112

Robert Greene Sterne  
 Jorge A. Goldstein  
 David K.S. Cornwell  
 Robert W. Esmond  
 Tracy-Gene G. Durkin  
 Michele A. Cimbala  
 Michael B. Ray  
 Robert E. Sokohl  
 Eric K. Steffe  
 Michael Q. Lee  
 John M. Covert  
 Robert C. Millonig  
 Donald J. Featherstone  
 Timothy J. Shea, Jr  
 Michael V. Messinger  
 Judith U. Kim  
 Jeffrey T. Helvey  
 Eldora L. Ellison  
 Donald R. Banowitz

Peter A. Jackman  
 Brian J. Del Buono  
 Mark Fox Evans  
 Vincent L. Capuano  
 Elizabeth J. Haanes  
 Michael D. Specht  
 Kevin W. McCabe  
 Glenn J. Perry  
 Theodore A. Wood  
 Edward W. Yee  
 Grant E. Reed  
 Jason D. Eisenberg  
 Tracy L. Muller  
 Jon E. Wright  
 LuAnne M. DeSantis  
 Helene C. Carlson  
 Cynthia M. Bouchez  
 Timothy A. Doyle  
 Gaby L. Longsworth

Lori A. Gordon  
 Laura A. Vogel  
 Shannon A. Carroll  
 Anbar F. Khal  
 Michelle K. Holoubek  
 Marsha A. Rose  
 Scott A. Schaller  
 Lei Zhou  
 W. Blake Coblenz  
 James J. Pohl  
 John T. Haran  
 Mark W. Rygiel  
 Michael R. Malek\*  
 Carla Ji-Eun Kim  
 Doyle A. Siever\*  
 Ulrike Winkler Jenks  
 Paul A. Calvo  
 C. Matthew Rozier\*  
 Randall K. Baldwin

Daniel J. Neviry  
 Lori M. Brandes  
 Jeffrey K. Mills\*  
 Mita Mukherjee\*  
 Scott M. Woodhouse\*  
 Christian A. Camarce\*  
 Richard D. Collier III\*  
 Keisha Hylton-Rodic  
 Bonnie Nannenga-Combs  
 Alyssa K. Sandrowitz\*  
 Jonathan M. Strang\*  
 Ishan P. Weeraakoon\*  
 Registered Patent Agents\*  
 Karen R. Markowicz  
 Matthew J. Dowd  
 Peter A. Socaras  
 Danielle L. Letting  
 Steven C. Oppenheimer

Aaron S. Lukas  
 Gaurav Asthana  
 Stephanie L. Elmer  
 Robert E. Bakin  
 Salvador M. Bezios  
 Yasser Mourtada  
 Of Counsel  
 Edward J. Kessler  
 Kenneth C. Bass III  
 Marvin C. Guthrie  
 Christopher P. Wrist  
 David C. Isaacson  
 \*Admitted only in Maryland  
 •Admitted only in Virginia  
 •Practice Limited to  
 Federal Agencies

August 5, 2008

Commissioner for Patents  
 PO Box 1450  
 Alexandria, VA 22313-1450

**WRITER'S DIRECT NUMBER:**  
 (202) 772-8822

**INTERNET ADDRESS:**  
 SCARROLL@SKGF.COM

**Art Unit 1652****Attn: Mail Stop Post Issue**

Re: U.S. Utility Patent No. 6,783,965; Issued: August 31, 2004  
 For: **Aggregate-Free Urate Oxidase for Preparation of Non-Immunogenic Polymer Conjugates**  
 Inventors: SHERMAN *et al.*  
 Our Ref: 2057.0080000/BJD/SAC

**Certificate**

AUG 26 2008

**of Correction**

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$130.00 to cover the fee for a Statutory Terminal Disclaimer for a large entity;
2. Executed Statutory Terminal Disclaimer Under 35 U.S.C. § 253 and 37 C.F.R. § 1.321(a); and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN &amp; FOX P.L.L.C.

Shannon A. Carroll, Ph.D.  
 Attorney for Patentees  
 Registration No. 58,240

SAC/nef  
 Enclosure(s)

856706\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:	Confirmation No.: 4303
Sherman <i>et al.</i>	Art Unit: 1652
U.S. Patent No. 6,783,965	Examiner: Pak, Yong D.
Issued: August 31, 2004	Atty. Docket: 2057.0080000/BJD/SAC
For: <b>Aggregate-Free Urate Oxidase for Preparation of Non-immunogenic Polymer Conjugates</b>	

**Statutory Terminal Disclaimer Under 35 U.S.C. § 253 and  
37 C.F.R. § 1.321(a)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

During prosecution of U.S. Appl. No. 09/501,730 which resulted in the issuance of the above-captioned patent, a Terminal Disclaimer was filed by Mountain View Pharmaceuticals, Inc. on December 4, 2003. Subsequent to execution of the Terminal Disclaimer and issuance of the above-captioned patent, inventorship was amended pursuant to 37 C.F.R. § 1.324(a). As a result, the above-captioned patent is now co-owned by Mountain View Pharmaceuticals, Inc. and Duke University. In view of the corrected inventorship, co-owner Duke University encloses an executed Terminal Disclaimer that also is executed by co-owner Mountain View Pharmaceuticals, Inc. Thus, so that the record of the above-captioned patent is clear, the co-owners hereby provide a joint Terminal Disclaimer.

Mountain View Pharmaceuticals, Inc. and Duke University represent that they are the owners of the entire right, title, and interest of U.S. Application No. 09/501,730, filed on February 10, 2000, and U.S. Patent No. 6,783,965 that issued therefrom, by virtue of:

KLJ 2667940.2

08/06/2008 JADDO1 00000060 6783965  
01 FC:1814 130 00 OP  
MJD

- (a) an Assignment from Merry R. Sherman, Mark G.P. Saifer and L. David Williams to Mountain View Pharmaceuticals, Inc. executed on April 26, 2000, recorded on May 22, 2000, at Reel 010836, Frame 0572; and
- (b) an Assignment from Michael S. Hershfield and Susan J. Kelly to Duke University executed on May 16, 2006 and May 17, 2006 respectively, recorded on May 24, 2006, at Reel 017663, Frame 0313.

***Establishing Right of Assignee to Take Action Under 37 C.F.R. § 3.73(b)***

A Statement Under 37 C.F.R. § 3.73(b) establishing the right of the assignee to take action, with regard to the above-identified application and patent was filed for Mountain View Pharmaceuticals, Inc. on May 24, 2006. Additionally, a Statement Under 37 C.F.R. § 3.73(b) establishing the right of the assignee to take action, with regard to the above-identified application and patent, was also filed in the above-captioned matter for Duke University on May 24, 2006.

***Terminal Disclaimer***

Mountain View Pharmaceuticals, Inc. and Duke University, hereby disclaim, except as provided below, the terminal part of the statutory term of the above-captioned patent which would extend beyond the expiration date of the full statutory term of prior patent No. 6,576,235 as the term of said prior patent is defined in 35 U.S.C. §§ 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer.

The co-owners hereby agree that the above-captioned patent shall be enforceable for and during such period that it and the prior patent are commonly owned. The co-owners further acknowledge that this disclaimer is to be binding upon the grantees, assignees, their successors or assigns.

Atty. Dkt. No. 2057.0080000/BJD/SAC

KL3 2667940.2

MRS

In making the above disclaimer, the co-owners do not disclaim the terminal part of the term of the captioned patent that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 and 173 of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The co-owners also do not disclaim any term of the above-captioned patent that is extended pursuant to 35 U.S.C. § 156.

Atty. Dkt. No. 2057.0080000/BJD/SAC

MRS

In accordance with 37 C.F.R. § 1.321(a), this disclaimer is accompanied by the fee set forth in 37 C.F.R. § 1.20(d). We have read and understand 37 C.F.R. § 10.18(b).

For: Mountain View Pharmaceuticals, Inc.

Signature: Merry R. Sherman

Type or Print Name: Merry R. Sherman

Title: CEO and President

Date: July 17, 2008

For: Duke University

Signature: R

Type or Print Name: Robert L. Taber, Ph.D.  
Vice Chancellor,

Title: Corporate & Venture Development

Date: 7/21/07